Trending:
Comment
-
17 August 2018
After Zavante deal, Nabriva is poised to launch two first-in-class antibiotics
On July 24, Nabriva Therapeutics announced the acquisition of Zavante Therapeutics, a biotechnology company developing treatments for the infections that threaten hospitalized patients.
-
17 August 2018
Revlimid demonstrates positive phase III results in Indolent NHL
Celgene has announced positive new data for its leading blockbuster drug, Revlimid (lenalidomide), which earned revenues of $8.2bn in 2017.
-
16 August 2018
EMA gives PRIME status to promising Huntington’s treatment
PRIME is the European Medicines Agency (EMA) Priority Medicines scheme to support the development of medicines that meet a high unmet need.
-
16 August 2018
UK seeks harmony with EU CTR as NHS and pharma stockpile drugs
The Medicines Health Products Regulatory Agency has reaffirmed its commitment to follow the European Clinical Trials Regulation System (CTR) during the Brexit transition period, between March 2019 and December 2020.
-
14 August 2018
Pfizer/Lilly’s Phase III trial for tanezumab in osteoarthritis still draws caution
Pfizer and Eli Lilly’s tanezumab for osteoarthritis (OA) of the hip and knee may face hurdles to clear long-term efficacy and safety benchmarks.
-
14 August 2018
Survey shows pharma’s doubts over Brexit outcome
The pharmaceutical industry is one of the most dynamic in the UK and is a major contributor to the economy.
-
13 August 2018
Achillion’s C3G trial earmarked for success, despite slow recruitment
Achillion Pharmaceuticals is developing a therapy specifically for C3G, though it is expected to face patient enrollment hurdles that could affect an on-time readout of one of its ongoing Phase...
-
13 August 2018
UK drug stockpiling begins as CMOs complain of Brexit uncertainty
Sanofi, Novartis, AstraZeneca and Roche are among the companies planning to stockpile drugs in preparation for a no-deal Brexit, according to reports.
-
9 August 2018
Top companies in the IBD space
Currently there are five major companies that have approved branded drugs in the inflammatory bowel disease (IBD) market—Johnson & Johnson (J&J), AbbVie, Takeda, UCB, and Pfizer (the newest entrant with...
-
9 August 2018
Akcea’s cardiovascular drug should meet Phase III benchmarks before CVOT
Akcea Therapeutics should first plan for a Phase III clinical study for AKCEA-APO(a)-LRx to determine the exact levels of lipoprotein Lp(a) reduction and cardiovascular risk before proceeding to a cardiovascular...
